NYSE · TEVA

Teva Pharmaceutical Industries Limited

Healthcare · Drug Manufacturers - Specialty & Generic

$39.95

Up+$0.54 (+1.37%)

Updated Oct 27, 2026, 4:46 AM

SID Score

6.4/10

Composite research score

Smart Money

60/100

Neutral

Market cap: 34.61B
P/E ratio: -217.43
Dividend yield: 0.00%
52-week range: $18.88 – $42.02
Volume: 6.03M
Avg. volume: 11.34M

Price performance · TEVA

TEVA price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 26, 2026

Last close: $39.95
Period change: +2.75%
Period low: $38.88
Period high: $41.50

Daily close

View OHLC price history

TEVA OHLC price history, latest 40 sessions
Date	Open	High	Low	Close	Volume
Oct 26, 2026	$39.22	$40.115	$39.15	$39.95	6.03M
Oct 23, 2026	$39.75	$39.8399	$39.105	$39.41	5.6M
Oct 22, 2026	$40.20	$40.445	$39.58	$40.21	4.07M
Oct 21, 2026	$40.18	$41.09	$39.50	$40.62	4.6M
Oct 20, 2026	$41.48	$41.59	$40.80	$40.85	4.22M
Oct 19, 2026	$41.42	$41.8792	$41.25	$41.31	3.83M
Oct 16, 2026	$41.26	$41.70	$40.96	$41.50	5.99M
Oct 15, 2026	$41.30	$41.85	$41.03	$41.11	9.41M
Oct 14, 2026	$41.11	$41.87	$40.71	$40.72	10.27M
Oct 13, 2026	$41.23	$41.65	$40.965	$41.25	6.82M
Oct 12, 2026	$41.29	$41.49	$40.60	$41.17	7.56M
Oct 9, 2026	$40.22	$42.02	$40.12	$41.10	14.82M
Oct 8, 2026	$38.84	$39.64	$38.25	$39.25	5.82M
Oct 7, 2026	$38.925	$39.39	$38.645	$39.18	3.46M
Oct 6, 2026	$39.65	$39.93	$38.85	$39.13	5.72M
Oct 5, 2026	$39.44	$40.03	$39.27	$39.66	4.15M
Oct 2, 2026	$39.31	$39.81	$39.05	$39.53	4.77M
Oct 1, 2026	$39.50	$39.58	$38.52	$39.31	5.99M
Sep 30, 2026	$40.20	$40.275	$39.22	$39.60	5.65M
Sep 29, 2026	$38.90	$40.24	$38.665	$39.81	6.82M
Sep 28, 2026	$38.36	$39.11	$38.30	$38.88	4.31M

Latest TEVA news

The latest Smart Investors Daily articles mentioning TEVA.

institutionalJul 30, 2026

Lingotto Investment Management LLP Reduces Holdings in Teva Pharmaceutical Industries Limited (TEVA)

institutionalJul 23, 2026

MEITAV INVESTMENT HOUSE LTD Initiates New Position in Teva Pharmaceutical Industries Limited (TEVA)

institutionalFeb 6, 2026

Phoenix Financial Ltd. Initiates New Position in Teva Pharmaceutical Industries Limited (TEVA)

Latest TEVA news

The latest Smart Investors Daily articles mentioning TEVA.

TEVA research

Overview

Company profile and research snapshot.

Company profile

Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus: —
Average target: $32.67
Implied upside: —
Analysts: —

TEVA recent ratings
Date	Firm	Rating	Target
Nov 25, 2020	Oppenheimer	Perform	—
Nov 6, 2020	BMO Capital	Market Perform	—
Aug 6, 2020	SVB Leerink	Market Perform	—
Aug 6, 2020	Barclays	Equal-Weight	—
Jul 27, 2020	Goldman Sachs	Neutral	—

Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 23, 2026

Teva Pharmaceutical Industries (TEVA) Secured WELTRUZA Approval, Is It Still 16% Below Fair Value?

Teva Pharmaceutical Industries stock: why WELTRUZA’s FDA approval matters now Teva Pharmaceutical Industries (NYSE:TEVA) just secured U.S. FDA approval for WELTRUZA, a once monthly injectable olanzapine treatment for adult schizophrenia, with a special call scheduled the same day to discuss the development. Recent performance has been strong for Teva Pharmaceutical Industries, with the share price delivering a 41.6% return over the past 90 days and a 22.4% share price return year to date,...

Yahoo · Oct 23, 2026

Dr. Reddy's Laboratories Q2 Earnings Call Highlights

Dr. Reddy's Laboratories (NYSE:RDY) reported second-quarter FY2027 revenue of INR 8,671 crore, or $905 million, down 1.5% from a year earlier but up 7.4% sequentially, as lower North American lenalidomide sales offset growth in its underlying business. Chief Financial Officer M.V. Narasimham said t

Fintel · Oct 23, 2026